Advances in bioresponsive closed-loop drug delivery systems

Jicheng Yu\textsuperscript{a,b}, Yuqi Zhang\textsuperscript{a,b}, Junjie Yan\textsuperscript{a,b,c}, Anna R. Kahkoska\textsuperscript{d}, Zhen Gu\textsuperscript{a,b,d,*}

\textsuperscript{a} Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC 27695, USA
\textsuperscript{b} Center for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
\textsuperscript{c} Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi 214063, PR China
\textsuperscript{d} Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA

A R T I C L E I N F O

Keywords:
Closed-loop
Drug delivery
Bioresponsive
Glucose-responsive
Enzyme-responsive

A B S T R A C T

Controlled drug delivery systems are able to improve efficacy and safety of therapeutics by optimizing the duration and kinetics of release. Among them, closed-loop delivery strategies, also known as self-regulated administration, have proven to be a practical tool for homeostatic regulation, by tuning drug release as a function of biosignals relevant to physiological and pathological processes. A typical example is glucose-responsive insulin delivery system, which can mimic the pancreatic beta cells to release insulin with a proper dose at a proper time point by responding to plasma glucose levels. Similar self-regulated systems are also important in the treatment of other diseases including thrombosis and bacterial infection. In this review, we survey the recent advances in bioresponsive closed-loop drug delivery systems, including glucose-responsive, enzyme-activated, and other biosignal-mediated delivery systems. We also discuss the future opportunities and challenges in this field.

1. Introduction

In living organisms, homeostatic regulation plays a critical role in enabling precisely tuned functionality in dynamic and variable environments, such as hormones secretion, ionic balance, and immune response (Fink, 1979; Lenardo et al., 1999). Homeostatic dysregulation is central to the pathogenesis of diseases such as diabetes and other autoimmune diseases (Gambineri et al., 2003; Mo et al., 2014). During the last few decades, closed-loop drug delivery systems have been explored as a promising alternative to conventional drug delivery for homeostatic regulation (Gordijo et al., 2011; Lee et al., 2013; Ravaine et al., 2008). Unlike open-loop systems including immediate-release and sustained-release formulations, these smart drug delivery systems release therapeutics with tunable amount at the right time, thus controlling drug release as a function of biosignals relevant to pathological processes (Byrne et al., 2002; Caldorera-Moore et al., 2011) (Fig. 1). One typical example is the closed-loop insulin delivery system, which releases insulin only in conditions where it is appropriate, such as rising blood glucose levels (Veiseh et al., 2015; Yu et al., 2016a; Zhang et al., 2015).

The closed-loop drug delivery systems usually consist of a monitoring component that senses the surrounding conditions and an actuator component with the capability to trigger drug release (Lu et al., 2016; Mura et al., 2013; Stuart et al., 2010). The pairing of the monitor/actuator architecture allows the drug release activated at or above a certain biosignal concentration or threshold but inhibited when the biosignal level is in normal ranges (Bawa et al., 2009; Lu et al., 2014; Park, 2014). Closed-loop medical devices consisting of a continuous sensor and an external drug infusion pump is one typical type of self-regulated drug delivery systems. Besides, a chemical approach based on bioresponsive materials has also received a great attention during the last few decades. In this review, we will summarize the recent advances in the development of closed-loop drug delivery systems based on bioresponsive materials, including glucose-responsive, enzyme-activated, and other biosignal-controlled systems. The challenges and future opportunities will also be discussed.

2. Glucose-responsive closed-loop insulin delivery systems

Properly dosed and timed insulin is essential to regulate blood glucose level for individuals with type 1 diabetes and advanced type 2 diabetes (Owens et al., 2001; Veiseh et al., 2015). Traditional open-loop insulin delivery requires frequent blood sugar monitoring and multiple subcutaneous injections with or after meals (Atkinson and Eisenbarth, 2001;
However, there are deep challenges associated with the open insulin delivery method that prevents patients from obtaining tight glucose control, increasing the risk for diabetic complications including blindness, limb amputation, and kidney failure (Atkinson and Eisenbarth, 2001; Bratlie et al., 2012). A closed-loop system mimicking the pancreatic beta cells to “secrete” insulin in response to blood glucose levels has been considered as a desirable strategy for the treatment of type 1 and advanced type 2 diabetes (Mo et al., 2014; Veiseh et al., 2015). Such systems are typically comprised of a glucose-sensing module and a relevant actuator. Although closed-loop electronic/mechanical devices comprising of a continuous glucose monitoring and an insulin infusion pump have been already developed, some challenges still need to be addressed such as achieving accurate signal feedback and avoiding biofouling. An alternative approach to achieve closed-loop insulin delivery is based on glucose-responsive chemical materials. We will introduce recent glucose-responsive closed-loop insulin delivery systems based on glucose oxidase (GOx), glucose binding proteins (GBPs), and phenylboronic acid (PBA), respectively.

2.1. Glucose oxidase (GOx)-based systems

2.1.1. pH

pH-sensitive polymeric matrix containing glucose oxidase (GOx) was developed as the first glucose-responsive material in the 1980s (Fischel-Ghodsian et al., 1988). As a glucose sensing element, GOx reacts with glucose in the presence of oxygen and converts it into gluconic acid, leading to a decrease in pH (Bankar et al., 2009; Chen et al., 2013). The pH-sensitive polymeric matrix subsequently responds to the pH change, swelling to facilitate insulin release. Peppas and coworkers also applied

Fig. 1. Schematic of the mechanism of closed-loop drug delivery systems that can adjust the release rate to the biosignal levels.

Fig. 2. (A) Schematic of the formation and release mechanism of glucose-responsive vesicles (GRVs) and GRVs-loaded MNs for in vivo insulin delivery. (B) A scanning electron microscope (SEM) image of GRVs-loaded MNs. Scale bar: 200 μm. (C) Blood glucose levels of diabetic mice treated with blank MNs made from HA, MNs loaded with insulin, MNs loaded with GRVs containing insulin and enzyme (GRV(E + I)), MNs loaded with GRVs containing insulin and half dose of enzyme (GRV(1/2E + I)), and MNs loaded with GRVs containing only insulin (GRV(I)). Reproduced with permission from Ref. (Yu et al., 2015).
H2O2-sensitive nanovesicles into a painless microneedle patch for the water-solubility of the polymer and facilitating the gradual disassembly of the nanovesicles upon exposure to high glucose concentrations, the rapidly-generated H2O2 readily reacted with the block polymer to degrade the pendant PBE, improving the water-solubility of the polymer and enhancing biocompatibility of the device.

2.2. Glucose binding proteins (GBPs)-based systems

Over the last decade, many glucose-responsive insulin delivery strategies have been exploited based on the selective binding between GBPs and glucose (Liu et al., 1997; Veiseh et al., 2015; Yu et al., 2016a). A lectin from the jack bean, concanavalin A (Con A), is commonly used as the glucose sensing moiety (Parmpi and Kofinas, 2004). Con A has four binding sites for reversible affinity to α-glucose, β-mannose, and polysaccharides (Brownlee and Cerami, 1979; Sharon and Lis, 1972). In the 1970s, Brownlee and Cerami first applied Con A to design a glucose-responsive insulin delivery system, where a glucosylated insulin derivative was synthesized and bound to Con A (Brownlee and Cerami, 1979). In the presence of high glucose concentrations, the insulin derivative was released by competitive displacement of free glucose. Kim and coworkers also synthesized glucan acid–modified insulin to complementarily bind to Con A for self-regulated insulin release (Makino et al., 1990; Seminoff et al., 1989). In addition, the reversible binding between Con A and polysaccharides like dextran and chitosan allows the fabrication of glucose-responsive hydrogel materials. For instance, Nie and coworkers developed glucose-triggered insulin hydrogels that could release insulin due to swelling and hydrolysis in the presence of increasing glucose levels (Yin et al., 2012, 2014).

Recently, Gu and coworkers utilized native red blood cells as the drug carriers to achieve glucose-responsive insulin delivery (Wang et al., 2017). The glucosamine-modified insulin derivative (Glc-Insulin) can bind to the glucose transporter (GLUT), an abundant membrane protein on red blood cells (Mueckler, 1994). Since this affinity is reversible, Glc-Insulin is quickly released from the red blood cells due to the competitive interaction of free glucose with GLUTs in hyperglycemic conditions. Using the chemically-induced type 1 mouse model, they demonstrated that single intravenous injection of these “glucose-responsive cells” was able to reduce the blood glucose levels for 3 days. Since red blood cells have a long life span of about 100 days, these insulin-loaded cells have a potential for in vivo long-term glucose-responsive insulin delivery (Muzikantov, 2010). The same authors also synthesized RBC membranes cloaked nanoplastforms for closed-loop insulin delivery based on the same mechanism (Wang et al., 2017).

2.3. Phenylboronic acid (PBA)-based systems

PBA is a synthetic molecule that can interact with diols to form a 5-or 6-membered ring cyclic boronate ester (Kataoka et al., 1995). Even since the reversible binding between PBA and sugar was discovered by Lorand and Edwards in 1959, PBA-based devices have been widely exploited for diabetes diagnosis, glucose sensors, and closed-loop insulin delivery (Brooks and Sumerlin, 2015; Bull et al., 2012; Lorand and Edwards, 1959).

Kataoka, Okana and coworkers described a glucose-responsive insulin device composed of glycosylated insulin-loaded PBA gel beads via the formulation of boronate ester (Shiino et al., 1994), where the PBA gel beads released insulin in response to environmental glucose
concentrations. Lin and coworkers applied PBA-modified mesoporous silica nanoparticles (PBA-MSNs) as the carriers for a glucose-responsive drug delivery system in which the gluconic acid–modified insulin could link to the PBA groups on the surface of PBA-MSNs and also act as the gatekeepers to entrap another drug, cyclic adenosine monophosphate (cAMP), in the pores of MSNs (Zhao et al., 2009). The insulin and cAMP release rates were controlled by blood glucose levels. In addition to the hypoglycemic effect induced by insulin, the released cAMP was able to further stimulate the insulin secretion from pancreas β cells, achieving self-regulated drug delivery.

Kim and coworkers further leveraged the charge transition in PBA molecules associated with glucose binding to design glucose-responsive polymersomes (Kim et al., 2012). They synthesized an amphiphilic block copolymer composed of a monosaccharide-sensitive poly(styreneboroxole) (PBOx) segment and a hydrophilic PEG block, which self-assembled into polymeric vesicles to encapsulate insulin. In hyperglycemic conditions, the PBOx block could interact with glucose to transform from an undissociated, neutrally charged form to a dissociated anionic form, leading to the dissociation of the polymersomes and subsequent insulin release. Matsumoto et al. investigated a glucose-responsive hydrogel based on a PBA-conjugated thermo-sensitive polymer (Matsumoto et al., 2012). The dehydrated surface served as a “skin layer” to control the insulin diffusion from the gel, while the glucose-mediated shift from the uncharged PBA to the charged form altered the volume of the gel, resulting in a rapid insulin release in hyperglycemic conditions. The glucose-induced phase transition allowed this insulin-loaded gel act as a closed-loop device to realize human-glucose homeostasis.

3. Enzyme-responsive closed-loop delivery systems

Enzymes play a central role in many biological and metabolic processes and the dysregulation of enzyme expression is associated to the progression of many diseases (Hu et al., 2014; Lee et al., 2004; Turk, 2006). Therefore, specific enzymes act as important signals for diagnosis as well as promising triggers for specific drug delivery (De La Rica et al., 2012). In enzyme-responsive closed-loop delivery systems, the activity or the overexpression of enzymes are suppressed following the action of the released drug. Then, enzyme-triggered drug release is turned off to avoid potential side effects.

3.1. Thrombin

For example, thrombin is responsible for converting soluble fibrinogen to insoluble fibrin and acts as the key enzyme in blood coagulation cascade (Mackman, 2008). Abnormal increases in blood thrombin levels can cause vascular occlusions and severe cardiovascular diseases (Engelmann and Massberg, 2013). Heparin is a common anticoagulant used in precise doses to counteract such coagulation activation (Collins et al., 1988). To more precisely dose heparin levels and prevent associated side effects, Maitz et al. designed a direct control loop system to deliver heparin in amounts tuned by the environmental thrombin levels (Maitz et al., 2013). In this system, heparin was covalently linked to multi-armed PEG through a thrombin-cleavable peptide to form a thrombin-responsive polymeric hydrogel (Fig. 4A). When thrombin levels increased, heparin was rapidly released due to the cleavage of the peptides, after which the free heparin is able to accelerate the formation of the complexation of thrombin and antithrombin, a natural thrombin inhibitor. This downregulation of the trigger (thrombin) caused by release of heparin creates a feedback loop, allowing for the sensitive control the thrombin activity and the associated regulation of anticoagulation activity. This closed-loop hydrogel was shown to effectively prevent the formation of blood clots over several hours during repeated incubation with fresh blood, while non-responsive heparin-loaded hydrogel could only quench blood coagulation in the first incubation with whole blood when heparin was released in full.

Utilizing the thrombin-cleavable peptide, Lin et al. also reported an electrostatic nanocomplex consisting of anionic heparin and cationic peptides for homeostatic regulation of the coagulation cascade (Lin et al., 2014). The thrombin-triggered cleavage of the peptides facilitated self-titrating anticoagulation activity that simultaneously...
decreased the risk of unwanted bleeding. Similarly, Bhat et al. applied the thrombin-responsive peptide as a gatekeeper to control the release of acenocoumarol, another anticoagulant drug, from mesoporous silica nanoparticles (MSNs) (Bhat et al., 2016). In order to achieve continuous, prolonged, convenient, and painless administration, Zhang et al. integrated a thrombin-responsive heparin-loaded hydrogel with a transcutaneous microneedle-array patch for auto-anticoagulant regulation, where the heparin was conjugated to a hyaluronic acid (HA) hydrogel via the thrombin-cleavable peptide (Fig. 4B) (Zhang et al., 2016). Once inserted into skin, this transcutaneous patch could sense the thrombin levels in capillary blood circulation, and there was little drug leaked from the patch in normal blood environments. However, the system effectively responded to the elevated thrombin level by releasing a proper dose of heparin to avoid blood clots. In vivo studies, the researchers demonstrated that this bioresponsive patch could effectively prevent undesirable coagulation. Furthermore, unlike the non-responsive heparin-loaded patch, the patch with feedback-controlled capability provided a long-term protection from acute pulmonary thromboembolism that lasted 6-hour post administration.

3.2. Lipase

Secreted lipases act as important persistence and virulence factors in the event of bacterial and fungal infections (Singh and Mukhopadhyay, 2012). Therefore, a lipase-activated drug delivery system has been explored to specifically inhibit bacterial and fungal growth. For example, Wang and coworkers described a lipase-sensitive polymeric triple layered nanogel for bacterial-activated drug delivery (Xiong et al., 2012). The model antimicrobial drug was entrapped in the polyphosphoester core and surrounded with hydrophobic poly(ε-caprolactone) (PCL) segments and hydrophilic PEG to prevent nonspecific antibiotic release (Fig. 5). When the nanogels were in the presence of lipase-secreting bacteria, the PCL layer was gradually degraded to release the antimicrobial drug to inactivate bacteria and subsequently reduce lipase secretion. This triple-layered nanogel exhibited significant efficiency to treat extracellular and intracellular bacterial infections without potential side effects. Another lipase-triggered formulation was reported by Loh and coworkers for potential treatment of fungal infection, where the lipase-sensitive polymer, polysorbate 80, was used to stabilize the phytantriol nanoparticles (Poletto et al., 2016). Lipase-mediated hydrolysis of polysorbate 80 to give polyethoxylated sorbitan and oleic acid resulted in a structural transition of the nanoparticle and consecutively triggered specific drug release. Aside from lipases, specific enzymes associated with different bacterial strains have also been recently exploited as the triggers to realize on-demand delivery of antimicrobial agents for bacterial strain-selective inhibition (Li et al., 2016).

Lipase is also a key enzyme for hydrolysis and absorption of food in the digestive tract, and partial deactivation of lipase can inhibit excess fat digestion and balance calorie intake (de la Garza et al., 2011).
Therefore, Shen and coworkers developed a smart lipase-responsive drug delivery system for negative feedback regulation of lipase activity (Chen et al., 2016). The lipase-degradable PCL was modified to the side chains of the fluorescent conjugated polymers, and the resulting amphiphilic copolymer was self-assembled into nanoparticles to encapsulate the lipase inhibitor drug, orlistat. Following oral administration, lipase released in the intestine catalyzed the degradation of the nanoparticles to release orlistat; the released orlistat irreversibly deactivated the lipase to reduce the intestinal absorption of dietary fats. Meanwhile, the inactivation of lipase shut down the degradation of the nanoparticles to tune the orlistat release rate in a negative feedback manner. In this closed-loop strategy, the nanoparticles were shown to be efficient in prevention of weight gain in a diet-induced obesity mouse model with few side effects.

4. Others biosignals-controlled closed-loop systems

4.1. CO2

Closed-loop drug delivery systems also hold great promise for the controlled release of antidotes in response to opioid overdose. Morphine, an opiate analgesic, is administered to relief both acute and chronic severe pain (Coban et al., 2007). However, morphine overdoses decrease reduced respiratory effort and lower blood pressure, resulting in decreased blood O2 levels, increased CO2 concentration and acidosis-induced death (Le Le Guen et al., 2002). An on-demand delivery of antidote can effectively eliminate the risk of morphine overdose. Therefore, Heller and coworkers developed a morphine-triggered antidote delivery device consisting of an enzyme-coated erodible polymeric core loaded with drug and a cellulose dialysis tube with enzyme lipases inactivated by the covalent conjugation with morphine and complexing with an antibody to morphine (Roskos et al., 1995). Free morphine is able to displace the lipase-morphine complex from antibody and allow the rapid degradation of polymeric core to release drug. Satav et al. designed another self-regulated antidote delivery system by taking advantage of CO2 as a danger signal (Satav et al., 2010). The CO2-responsive hydrogel-based delivery vehicle was prepared from functional N,N-dimethylaminoethyl methacrylate (DMAEMA) monomer and trimethylolpropane trimethacrylate (TMPTMA) crosslinker. In the presence of increased blood CO2 levels and the associated decrease in pH, the protonation of the amine groups of DMAEMA causes the swelling of the pH-sensitive hydrogel and accelerates drug release. This system’s remarkable control of antidote release against the toxic marker concentration has great potential to prevent serious side effects of drug overdose.

4.2. Urea

Urea-responsive drug delivery has also been explored based on the enzymatic activity of urease, which hydrolyses urea into NH4HCO3 and NH3OH (Krajewska, 2009). As this enzymatic reaction causes an increase in pH, Heller and Trescony developed a urea-responsive delivery device based on a pH-sensitive bioerodible polymer (Heller and Trescony, 1979). A model drug, hydrocortisone, was mixed with a partially esterified copolymer of methylvinylether and maleic anhydride to fabricate into disks, which were coated with urease-imobilized hydrogel. In the presence of external urea, the pH increase was able to accelerate the polymer erosion and drug release. Similarly, Ishihara et al. designed a pH-sensitive membrane instead of the erodible polymer for urea-responsive closed-loop delivery (Ishihara et al., 1985a, b). The permeation of the drug through the 4-carboxy acrylamide-methyl methacrylate membrane was modulated by change in pH caused by the urease-mediated urea conversion.

4.3. Ions

Based on the many kinds of cations and anions in body fluids such as blood, gastrointestinal fluid, sweat and tears, ion-responsive delivery systems can sense a variety of ions concentrations in body fluid and modulate the drug release rate for optimal drug therapy. For instance, Na+ ion commonly exists in the wound exudates and Huang et al. described a Na+-sensitive alginate gel loaded with nano-silver as a non-specific antimicrobial agent for wound dressing applications (Huang et al., 2015). Upon administration to the wound, the alginate gel swelled due to the ion-exchange of Na+, thereby opening the lock between Ca2+ and guluronic residues on alginate to result in subsequent release of nano-silver. Since the extent of alginate gel swelling was tuned by the volume of wound exudates, the release rate of nano-silver was effectively self-regulated during the wound healing process, achieving a closed-loop drug delivery strategy. Chu and coworkers also developed a K+-sensitive hydrogel consisting of crown ether 15-crown-5 as the ion-sensor and poly(N-isopropylacrylamide) as the actuator for self-regulated controlled release (Mi et al., 2010). In this system, K+ bound to the crown ether 15-crown-5 based on a 2:1 “host-guest” complexation formulation to drive the shrinkage of the hydrogel, giving a pulse-release mode that was regulated by changing environmental K+ concentration.

5. Conclusions and future directions

During the past several decades, many sensing mechanisms have emerged, which provide new control strategies for designing closed-loop drug delivery systems. For such systems, numerous bioresponsive materials are utilized to construct functional modules for the desired devices. Therapeutics is designed to be controlled released from drug carriers through the structural transformations such as shrinking, swelling, and dissociation or unique responsive cleavage route. Table 1 summarizes the typical closed-loop drug delivery systems recently reported in this review. These emerging smart devices have been proven to be capable to enhance therapy efficiency and reduce adverse effect in drug administration, demonstrating vast potential in fields including diabetes management, auto-anticoagulation regulation, and antibiotic therapy in both the research and the clinical sector. Despite the advancements, translation of a clinically effective and safe closed-loop delivery system remains challenged by several aspects. For example, in order to achieve the precise delivery, relevant parameters of materials and formulation should be carefully tailored. Meanwhile, it is important to set uniformity for the evaluation of the devices in clinical trials. Second, a thorough understanding of the role of biosignals in diseases is
required to design an effective closed-loop system. It is critical to differentiate the target biosignal from its analogues to enhance specificity of delivery systems. Moreover, long-term prevention and treatment with closed-loop systems requires sufficient sustained biocompatibility. Thorough assessment of materials and effective elimination of toxic substance must be taken into consideration. Aside from these challenges, identifying and leveraging new monitor/actuator pairs is also important to design novel closed-loop drug delivery devices, especially those that may be used for prevalent metabolic diseases (Bakh et al., 2017).

Acknowledgments

This work was supported by the grants from the American Diabetes Association (ADA) (grant no. 1-15-ACE-21) and National Science Foundation (grant no. 1708620) to Z.G.)

References

Ishihara, K., Muramoto, N., Fujii, H., Shinozuka, L., 1985b. Preparation and permeability...


